HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

• Volk JE,
• Hessol NA,
• Gray GE,
• Kublin JG,
• Churchyard G,
• Mlisana K,
• Nchabeleng M,
• Buchbinder SP,
• Bekker L

Affiliations

Volk JE

Hessol NA

Gray GE

Kublin JG

Churchyard G

Mlisana K

Nchabeleng M

Buchbinder SP

Bekker L